Chief Executive Officer · Connect Biopharma Holdings Ltd (CNTB)

Barry Quart

A named executive officer of Connect Biopharma in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$2,507,764

Salary $660,800Stock awards $0

FY2024: $4,521,436

1st of 3 named executive officers at Connect Biopharma by FY2025 total.

3 named officers on file for Connect Biopharma, FY2025

Barry Quart’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Connect Biopharma’s whole pay program stands against its peers

  • Connect Biopharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CNTB→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 31, 2026 (10-K).

Free

Get Barry Quart’s full pay file as a PDF — free

More than this page: up to 10 years of Barry’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Barry Quart compensation by year

Connect Biopharma Summary Compensation Table · all 2 fiscal years held
In US dollars, as Connect Biopharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$360,208$660,800
Bonus$0$0
Stock awards$0$0
Option awards$3,973,970$1,527,540
Non-equity incentive$178,065$308,924
Pension and deferred compensation$0$0
All other$9,193$10,500
Total$4,521,436$2,507,764

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Connect Biopharma Holdings Ltd 10-K filed March 31, 2026, accession 0001835268-26-000013, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Connect Biopharma Holdings Ltd filed document, accession 0001835268-26-000013. Every figure is read from that document and cited to the page and table it appears in. Filed March 31, 2026.

$4.5M
$2.5M
FY24
FY25
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option1,661,709—$1.77
Option324,294—$0.97
Option700,000—$2.69

Per the Outstanding Equity Awards at Fiscal Year-End table in Connect Biopharma Holdings Ltd's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Connect Biopharma’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Barry Quart · this pageChief Executive Officer$2,507,764
David SzekeresPresident$1,607,850
Lisa PerazaSenior Vice President, Finance$1,154,787

The full Connect Biopharma compensation record

free company brief

This page is one person within Connect Biopharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Connect Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Barry Quart's compensation dossier · One-time report. No refunds.